Literature DB >> 23324395

Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1.

C Elizabeth Caldon1, C Marcelo Sergio, Andrew Burgess, Andrew J Deans, Robert L Sutherland, Elizabeth A Musgrove.   

Abstract

Cyclins E1 drives the initiation of DNA replication, and deregulation of its periodic expression leads to mitotic delay associated with genomic instability. Since it is not known whether the closely related protein cyclin E2 shares these properties, we overexpressed cyclin E2 in breast cancer cells. This did not affect the duration of mitosis, nor did it cause an increase in p107 association with CDK2. In contrast, cyclin E1 overexpression led to inhibition of the APC complex, prolonged metaphase and increased p107 association with CDK2. Despite these different effects on the cell cycle, elevated levels of either cyclin E1 or E2 led to hallmarks of genomic instability, i.e., an increased proportion of abnormal mitoses, micronuclei and chromosomal aberrations. Cyclin E2 induction of genomic instability by a mechanism distinct from cyclin E1 indicates that these two proteins have unique functions in a cancer setting.

Entities:  

Keywords:  cyclin E1; cyclin E2; genomic instability; mitosis; p107

Mesh:

Substances:

Year:  2013        PMID: 23324395      PMCID: PMC3594261          DOI: 10.4161/cc.23512

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  57 in total

1.  Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest.

Authors:  Navdeep K Dhillon; Maria Mudryj
Journal:  Oncogene       Date:  2002-07-11       Impact factor: 9.867

2.  The helix-loop-helix protein Id1 requires cyclin D1 to promote the proliferation of mammary epithelial cell acini.

Authors:  C Elizabeth Caldon; Alexander Swarbrick; Christine S L Lee; Robert L Sutherland; Elizabeth A Musgrove
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

3.  p53 and p21 form an inducible barrier that protects cells against cyclin E-cdk2 deregulation.

Authors:  Alex C Minella; Jherek Swanger; Eileen Bryant; Markus Welcker; Harry Hwang; Bruce E Clurman
Journal:  Curr Biol       Date:  2002-10-29       Impact factor: 10.834

4.  Cyclin D1 overexpression induces progestin resistance in T-47D breast cancer cells despite p27(Kip1) association with cyclin E-Cdk2.

Authors:  E A Musgrove; L J Hunter; C S Lee; A Swarbrick; R Hui; R L Sutherland
Journal:  J Biol Chem       Date:  2001-10-04       Impact factor: 5.157

5.  Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication.

Authors:  K Nakayama; H Nagahama; Y A Minamishima; M Matsumoto; I Nakamichi; K Kitagawa; M Shirane; R Tsunematsu; T Tsukiyama; N Ishida; M Kitagawa; K Nakayama; S Hatakeyama
Journal:  EMBO J       Date:  2000-05-02       Impact factor: 11.598

6.  Cyclin A1 directly interacts with B-myb and cyclin A1/cdk2 phosphorylate B-myb at functionally important serine and threonine residues: tissue-specific regulation of B-myb function.

Authors:  C Müller-Tidow; W Wang; G E Idos; S Diederichs; R Yang; C Readhead; W E Berdel; H Serve; M Saville; R Watson; H P Koeffler
Journal:  Blood       Date:  2001-04-01       Impact factor: 22.113

7.  A mouse model for cyclin E-dependent genetic instability and tumorigenesis.

Authors:  Keith R Loeb; Heather Kostner; Eduardo Firpo; Thomas Norwood; Karen D Tsuchiya; Bruce E Clurman; James M Roberts
Journal:  Cancer Cell       Date:  2005-07       Impact factor: 31.743

8.  string(cdc25) and cyclin E are required for patterned histone expression at different stages of Drosophila embryonic development.

Authors:  David J Lanzotti; Jeremy M Kupsco; William F Marzluff; Robert J Duronio
Journal:  Dev Biol       Date:  2004-10-01       Impact factor: 3.582

9.  Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer.

Authors:  Said Akli; Ping-Ju Zheng; Asha S Multani; Hannah F Wingate; Sen Pathak; Ning Zhang; Susan L Tucker; Sandy Chang; Khandan Keyomarsi
Journal:  Cancer Res       Date:  2004-05-01       Impact factor: 12.701

10.  Chromatin decondensation in S-phase involves recruitment of Cdk2 by Cdc45 and histone H1 phosphorylation.

Authors:  Mark G Alexandrow; Joyce L Hamlin
Journal:  J Cell Biol       Date:  2005-03-07       Impact factor: 10.539

View more
  25 in total

1.  Increased sensitivity of HPV-positive head and neck cancer cell lines to x-irradiation ± Cisplatin due to decreased expression of E6 and E7 oncoproteins and enhanced apoptosis.

Authors:  Frank Ziemann; Andrea Arenz; Stefanie Preising; Claus Wittekindt; Jens P Klussmann; Rita Engenhart-Cabillic; Andrea Wittig
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

2.  Candidate pathways and genes for nasopharyngeal carcinoma based on bioinformatics study.

Authors:  Jinhui Chen; Rui Yang; Wei Zhang; Yongping Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

3.  AKAP95 promotes cell cycle progression via interactions with cyclin E and low molecular weight cyclin E.

Authors:  Xiang-Yu Kong; Deng-Cheng Zhang; Wen-Xin Zhuang; Su-Hang Hua; Yue Dai; Yang-Yang Yuan; Li-Li Feng; Qian Huang; Bo-Gang Teng; Xiu-Yi Yu; Wen-Zhi Liu; Yong-Xing Zhang
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

4.  Overexpression screens identify conserved dosage chromosome instability genes in yeast and human cancer.

Authors:  Supipi Duffy; Hok Khim Fam; Yi Kan Wang; Erin B Styles; Jung-Hyun Kim; J Sidney Ang; Tejomayee Singh; Vladimir Larionov; Sohrab P Shah; Brenda Andrews; Cornelius F Boerkoel; Philip Hieter
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-22       Impact factor: 11.205

5.  Tumor mutation burden is correlated with response and prognosis in microsatellite-stable (MSS) gastric cancer patients undergoing neoadjuvant chemotherapy.

Authors:  Ziyu Li; Yongning Jia; Honglin Zhu; Xiaofang Xing; Fei Pang; Fei Shan; Shuangxi Li; Danhua Wang; Fangping Zhao; Tonghui Ma; Sizhen Wang; Jiafu Ji
Journal:  Gastric Cancer       Date:  2021-08-18       Impact factor: 7.701

6.  Two unique HLA-A*0201 restricted peptides derived from cyclin E as immunotherapeutic targets in leukemia.

Authors:  Hong He; Yukio Kondo; Ken Ishiyama; Gheath Alatrash; Sijie Lu; Kathryn Cox; Na Qiao; Karen Clise-Dwyer; Lisa St John; Pariya Sukhumalchandra; Qing Ma; Jeffrey J Molldrem
Journal:  Leukemia       Date:  2020-01-06       Impact factor: 11.528

7.  Differences in regulation and function of E-cyclins in human cancer cells.

Authors:  Yan Geng; Piotr Sicinski
Journal:  Cell Cycle       Date:  2013-04-02       Impact factor: 4.534

Review 8.  Targeting cell-cycle machinery in cancer.

Authors:  Jan M Suski; Marcin Braun; Vladislav Strmiska; Piotr Sicinski
Journal:  Cancer Cell       Date:  2021-04-22       Impact factor: 38.585

9.  Comparing genotoxic signatures in cord blood cells from neonates exposed in utero to zidovudine or tenofovir.

Authors:  Alexandre Vivanti; Tayebeh S Soheili; Wendy Cuccuini; Sonia Luce; Laurent Mandelbrot; Jerome Lechenadec; Anne-Gael Cordier; Elie Azria; Jean Soulier; Marina Cavazzana; Stéphane Blanche; Isabelle André-Schmutz
Journal:  AIDS       Date:  2015-07-17       Impact factor: 4.177

10.  Similar, not the same: diverse roles and regulation of cyclin Es.

Authors:  Loredana Spoerri; Brian Gabrielli
Journal:  Cell Cycle       Date:  2013-02-19       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.